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Figure 2. Uptake of DAAs among Medicaid members with HCV, three New 
England states, by month, Dec, 2013 – June, 2018
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Methods
Principal Findings
Conclusion/Implications
Study Objectives
Study Population
• Prior to 2014, Hepatitis C Virus (HCV) treatment required 
injected interferon, with low efficacy and high side effects
• Direct acting antiviral (DAA) sofosbuvir (SOF) was 
introduced in December, 2013
• Shorter treatment duration, all-oral regimen for some
• Higher efficacy, fewer side effects, initially expensive
• All-oral regimen ledipasvir/sofosbuvir (LDV/SOF) was 
approved in October 2014; others followed
• Medicaid prior authorization (PA) requirements were 
initially common
• Prescribing provider specialist
• Abstinence or substance use disorder (SUD) treatment 
• Advanced HCV
• Medicaid plans lifted restrictions over time, following 
Nov, 2015 CMS guidance
• Analysis of early uptake of DAAs demonstrated that low 
numbers of individuals were treated 
Background Results
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Uptake of Direct Acting Antivirals for Hepatitis C Virus in a 
New England Medicaid Population, 2014-2017
• Examine the uptake of DAAs in Medicaid population of 
three New England states from Dec, 2013 – Dec, 2017
• Examine effect of introduction of LDV/SOF and lifting HCV 
PA restrictions on uptake
• Examine uptake by age and gender 
• Data Source: Enrollment, medical, and pharmacy claims 
from 13 Medicaid plans in three New England states, 
Dec, 2012 – Dec, 2017
• Study Population: Medicaid members ages 18-64 with a 
diagnosis of HCV between Dec, 2012 and Dec, 2017 and 
no evidence of previous HCV treatment
• While initial uptake of DAAs was low in this multi-state 
Medicaid population, treatment increased through 2017
• Introduction of new medications and lifting of PA 
restrictions was followed by an immediate increase in 
uptake followed by relatively flat monthly utilization 
Measures
Measure Definition Categories
HCV 
2+ claims with ICD code for HCV 
diagnosis in one year or 1+ claim 
for chronic HCV
Yes/No
DAA 
Uptake
1+ pharmacy claim for a DAA Yes/No
Age Age as of Dec, 2012
18-34; 35-49; 
50-64 years 
Gender Male/Female
PA 
Restrictions
Restriction in place in plan, by type:
- Prescribing provider specialist
- SUD
- Advanced HCV
Yes/No
• Members were included in the study population in each 
month from first HCV diagnosis until treated or left 
Medicaid
• Interrupted time series (ITS) with segmented 
autocorrelation-adjusted regression modeled trends in 
treatment uptake prior to and after two time points:
• Oct, 2014 (LDV/SOF approval date) 
• July, 2016  (date PA restrictions in 10 plans were lifted)
• Chi-square testing evaluated demographic differences in 
DAA uptake in 2014 and 2017
Plans 2014 2017
Total N 13 32,302 45,909
Percentage of sample 
from each state
State A 7 92% 90% 
State B 4 3% 4%
State C 2 5% 6%
2014 2017
N (%) N (%) 
Total 32,302 45,909
Age 
18 - 34 9,562 (30%) 13,856 (30%)
35- 49 10,637 (33%) 14,907 (32%)
50 - 64 12,103 (37%) 17,146 (37%)
Gender
Male 19,163 (59%) 27,063 (59%)
Female 13,139 (41%) 18,846 (41%)
• DAA uptake rose from 3.3% in 2014 to 7.7% in 2017 (p = 
<0.01 for trend). Cumulatively, 18% were treated by 2017 
• While uptake increased in the month following SOF 
introduction, uptake overall was flat until LDV/SOF was 
introduced, doubled in the month after approval and 
remained flat during the subsequent 20 months
• Uptake doubled again in the month following the lifting of 
PA restrictions then remained steady through 2017
• Uptake rose earliest among those ages 50-64 years; by 
2017 uptake was slightly higher in younger adults
• Throughout the period the percentage of men treated was 
higher than females
Policy implications
• Sharp increase in uptake after LDV/SOF introduction may 
indicate warehousing of members in anticipation of 
LDV/SOF approval
• Treatment rate increase after PA restrictions were lifted 
indicates demand among those affected by restrictions
• A large percentage of the Medicaid population with HCV 
remains untreated; planned provider interviews will 
identify barriers and facilitators to treatment for HCV
• Multi-state population provides wider range of member 
and plan characteristics than a single state analysis
Table 2. Number of Medicaid plans and 
percentage of study population across 
states, 2014 and 2017
Table 3. Demographic characteristics of 
Medicaid members with HCV,  2014 and 2017
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Table 1. Study measures
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Figure 3. Uptake of DAAs among Medicaid 
members with HCV, three New England 
States, by gender and year, 2014-2017
`
Figure 4. Uptake of DAAs among Medicaid 
members with HCV, three New England 
States, by age and year,  2014-2017
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Figure 1. Number of plans with PA restrictions on DAA, by type of 
restriction, by month, Dec, 2013 – Dec, 2017
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